Dr Eric Goosby, Sundar Kodiyalam, David Y Norton, and Sangita Reddy join board
TB Alliance, a not-for-profit organisation dedicated to development and delivery of improved regimens to fight tuberculosis (TB), has added four new members to its Board of Directors. Joining the Board are Dr Eric Goosby, Sundar Kodiyalam, David Y Norton and Sangita Reddy. These new members bring decades of experience in disciplines spanning drug development, public health policy, and health systems management and will help guide the organisation as it further expands its work in product delivery in addition to bolstering its research and development capacity.
Dr Goosby is an internationally recognised expert on infectious diseases. Dr Goosby was the founding director of the Ryan White CARE Act, the largest federally funded HIV/AIDS programme in the US. He went on to become the interim director of the White House’s Office of National AIDS Policy. In the Obama Administration, Dr Goosby was appointed Ambassador-at-Large and implemented the US President’s Emergency Plan for AIDS Relief (PEPFAR).
Sundar Kodiyalam co-founded the venture capital firm, Vatera Healthcare Partners, and was its Managing Director for more than ten years. Kodiyalam has decades of experience in the biotechnology and biopharmaceutical sectors, previously serving as Senior Vice President of Commercial Development & New Business Ventures at Kos Pharmaceuticals and Vice President of Commercial Development at Ortec International. Further, Kodiyalam served as Director of Business Development & Licensing at Schering-Plough Corporation and in domestic and international marketing roles at Novartis.
David Norton returns to TB Alliance’s Board of Directors, previously serving from 2012-2018. Norton spent 32 years at Johnson & Johnson, before retiring in 2011. He served as Company Group Chairman, Global Pharmaceuticals and was responsible for leading and developing the strategic growth agenda, including the strategy for licensing, acquisitions, and divestments, and ensuring alignment with global strategic functions, research and development and the commercial organisations.
In his previous tenure on TB Alliance’s Board of Directors, Norton’s knowledge of the pharmaceutical development industry and professional experience around the world proved valuable in shaping TB Alliance’s strategies, particularly around global partnerships.
Reddy is the Joint MD, Apollo Hospitals Enterprise. In this capacity, Reddy has been passionate about expanding access to healthcare throughout India and underserved regions of the world, the guiding force in Apollo’s research, innovation, and healthcare initiatives, and pivotal in influencing the development of the healthcare information technology industry in India.
“With its new therapies changing the TB treatment landscape, TB Alliance will continue to develop innovative products as well as expand delivery of new treatments,” said Dr Bruce Carter, Chairman of the Board, TB Alliance. “The addition of these distinguished members expands our expertise across both the public and private sector and reinforces our commitment to improved treatment for TB for all.”
